Trial Profile
Phase 1b Open Label Dose Assessment Study of ASLAN001 (Varlitinib) in Patients With Advanced/ Metastatic Hepatocellular Carcinoma (HCC) With an Expansion Cohort in HCC Patients Expressing HER3 Who Have Progressed on First Line Sorafenib or Lenvatinib
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Varlitinib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- 11 Sep 2017 New trial record
- 07 Sep 2017 According to an ASLAN Pharmaceuticals media release, National University Cancer Institute, Singapore (NCIS), a member of the National University Health System is associated with this trial.